Entocord 3 mg Modified-release hard capsules
PDF Leaflet Revision Date: 11 January 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Induction of remission in mild to moderate Crohn's disease.
Dosage (summary)
Adults: 9 mg once daily for up to 8 weeks.
Onset of Action / Duration
Onset: 2-4 weeks, Duration: up to 8 weeks
Special Populations
- Elderly
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy not established; excreted in breast milk.
Key Drug Interactions
- CYP3A inhibitors
- Grapefruit juice
Contraindications
- Hypersensitivity to budesonide
Common side effects
- Palpitations
- Dyspepsia
- Blurred vision
- Muscle cramps
Counselling Points
- Take in the morning
- Do not crush or chew capsules
- Monitor for visual disturbances
Serious warnings
- Risk of glaucoma
- Adrenal suppression
- Cushing's syndrome
Important Disclaimer
The Entocord 3 mg Modified-release hard capsules professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
